The Respond, Study Group (2020). How to RESPOND to Modern Challenges for People Living with HIV: A Profile for a New Cohort Consortium. Microorganisms, 8(8) MDPI 10.3390/microorganisms8081164
|
Text
microorganisms-08-01164.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (1MB) | Preview |
BACKGROUND
the International Cohort Consortium of Infectious Disease (RESPOND) is a collaboration dedicated to research on HIV and other infectious diseases.
METHODS
RESPOND is a flexible organization, with several independent substudies operating under one shared governance. HIV-related variables, including full antiretroviral therapy (ART) history, are collected annually for all participants and merged with substudy specific data into a shared data pool. Incident clinical events are reported using standardized forms. Prospective follow-up started 1/10/17 (enrolment) with retrospective data collected back to 01/01/12.
RESULTS
Overall, 17 cohorts from Europe and Australia provided data on 26,258 people living with HIV (PLWH). The majority (43.3%) of the population were white, with men-sex-with-men accounting for 43.3% of the risk for HIV acquisition. The median age was 48 years (IQR 40-56) and 5.2% and 25.5% were known to be co-infected with hepatitis B or C. While 5.3% were ART-naïve, the median duration on ART was 10.1 years (4.8-17.6), with 89.5% having a VL <200 copies/mL and the median CD4 count being 621 cells/µL (438-830). Malignancies (n = 361) and cardiovascular disease (n = 168) were the predominant reported clinical events.
CONCLUSION
RESPOND's large, diverse study population and standardized clinical endpoints puts the consortium in a unique position to respond to the diverse modern challenges for PLWH.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology |
ISSN: |
2076-2607 |
Publisher: |
MDPI |
Language: |
English |
Submitter: |
Annelies Luginbühl |
Date Deposited: |
10 Sep 2020 07:58 |
Last Modified: |
10 Sep 2020 07:58 |
Publisher DOI: |
10.3390/microorganisms8081164 |
PubMed ID: |
32752044 |
Additional Information: |
Prof. Dr. med. Gilles Wandeler ist Mitglied der Forschungruppe "The Respond Study Group" |
Uncontrolled Keywords: |
HIV cohort hepatitis observational study pharmacovigilance public health tuberculosis |
BORIS DOI: |
10.7892/boris.146431 |
URI: |
https://boris.unibe.ch/id/eprint/146431 |
Actions (login required)
 |
Edit item |